Patents by Inventor Matthew David Max Crispin

Matthew David Max Crispin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINED THERAPEUTIC USE OF ANTIBODIES AND IMMUNOGLOBULIN G-DEGRADING ENZYMES
    Publication number: 20230398212
    Abstract: The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.
    Type: Application
    Filed: August 21, 2023
    Publication date: December 14, 2023
    Inventors: Matthew David Max Crispin, Christopher Neil Scanlan, Julia Alison Sherriff
  • COMBINED THERAPEUTIC USE OF ANTIBODIES AND IMMUNOGLOBULIN G-DEGRADING ENZYMES
    Publication number: 20200345844
    Abstract: The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 5, 2020
    Inventors: Matthew David Max Crispin, Christopher Neil Scanlan
  • COMBINED THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES
    Publication number: 20170274070
    Abstract: The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 28, 2017
    Applicant: Immago Biosystems Ltd
    Inventors: Matthew David Max Crispin, Christopher Neil Scanlan
  • COMBINED THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES
    Publication number: 20150125443
    Abstract: The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 7, 2015
    Applicant: Immago Bisystems Ltd.
    Inventors: Matthew David Max Crispin, Christopher Neil Scanlan
  • EPITOPE REDUCTION THERAPY
    Publication number: 20100022620
    Abstract: The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease.
    Type: Application
    Filed: July 27, 2007
    Publication date: January 28, 2010
    Inventors: Matthew David Max Crispin, Christopher Scanlan, Frances Mary Platt, Hugh John Willison